EJNMMI Research

Table 2 Biodistribution (0.3 MBq/0.075 nmol) of ¹⁷⁷ Lu-labelled BN analogues in nude mice bearing PC-3 tumour

From: PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with ¹⁷⁷Lu-DOTA-bombesin analogues

	¹⁷⁷Lu-DOTA-Lys-BN		¹⁷⁷Lu-DOTA-PEG _5k-Lys-BN		¹⁷⁷Lu-DOTA-Lys-BN	¹⁷⁷Lu-DOTA-PEG _5k-Lys-BN
Tissue	1 h p.i.	24 h p.i.	1 h p.i.	24 h p.i.	1 h p.i. blocked	1 h p.i. blocked
Blood	0.24 ± 0.07	0.00 ± 0.00	1.54 ± 0.33*	0.01 ± 0.00*
Heart	0.14 ± 0.06	0.01 ± 0.01	0.49 ± 0.05	0.04 ± 0.01
Lung	0.36 ± 0.08	0.02 ± 0.01	1.10 ± 0.15	0.13 ± 0.02
Spleen	0.42 ± 0.12	0.18 ± 0.04	0.72 ± 0.02	0.19 ± 0.03
Kidneys	2.86 ± 0.63	1.41 ± 0.14	4.89 ± 1.33	1.84 ± 0.52
Pancreas	8.68 ± 1.95	4.27 ± 0.85	9.62 ± 2.39	4.87 ± 1.11	0.49 ± 0.22**	0.98 ± 0.59*
Stomach	0.72 ± 0.19	0.10 ± 0.02	1.12 ± 0.15	0.22 ± 0.07
Small intestine	1.38 ± 0.41	0.16 ± 0.03	1.18 ± 0.22	0.17 ± 0.12
Colon	1.64 ± 0.40	0.36 ± 0.09	2.19 ± 0.91	0.45 ± 0.21	0.36 ± 0.07**	0.66 ± 0.14
Liver	0.26 ± 0.09	0.09 ± 0.02	0.57 ± 0.04	0.16 ± 0.09
Muscle	0.20 ± 0.24	0.01 ± 0.00	0.31 ± 0.06	0.42 ± 0.69
Bone	0.36 ± 0.24	0.02 ± 0.01	0.70 ± 0.06	0.58 ± 0.44
Tumour	1.88 ± 0.47	0.54 ± 0.30	3.43 ± 0.63*	1.04 ± 0.04	0.55 ± 0.03*	1.02 ± 0.34**

*P < 0.05; **P < 0.01. Data in percentage of injected dose per gram of tissue (%ID/g), expressed as mean ± SD at 1 and 24 h p.i. (n = 3 to 4).

Back to article page